Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.

Iacobuzio-Donahue CA, Fu B, Yachida S, Luo M, Abe H, Henderson CM, Vilardell F, Wang Z, Keller JW, Banerjee P, Herman JM, Cameron JL, Yeo CJ, Halushka MK, Eshleman JR, Raben M, Klein AP, Hruban RH, Hidalgo M, Laheru D.

J Clin Oncol. 2009 Apr 10;27(11):1806-13. doi: 10.1200/JCO.2008.17.7188. Epub 2009 Mar 9.

2.

Immortalizing the complexity of cancer metastasis: genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy.

Embuscado EE, Laheru D, Ricci F, Yun KJ, de Boom Witzel S, Seigel A, Flickinger K, Hidalgo M, Bova GS, Iacobuzio-Donahue CA.

Cancer Biol Ther. 2005 May;4(5):548-54. Epub 2005 May 12.

3.

Adenosquamous carcinoma of the pancreas harbors KRAS2, DPC4 and TP53 molecular alterations similar to pancreatic ductal adenocarcinoma.

Brody JR, Costantino CL, Potoczek M, Cozzitorto J, McCue P, Yeo CJ, Hruban RH, Witkiewicz AK.

Mod Pathol. 2009 May;22(5):651-9. doi: 10.1038/modpathol.2009.15. Epub 2009 Mar 6.

4.

Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival.

Shin SH, Kim SC, Hong SM, Kim YH, Song KB, Park KM, Lee YJ.

Pancreas. 2013 Mar;42(2):216-22. doi: 10.1097/MPA.0b013e31825b6ab0.

PMID:
23344532
5.

Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.

Oshima M, Okano K, Muraki S, Haba R, Maeba T, Suzuki Y, Yachida S.

Ann Surg. 2013 Aug;258(2):336-46. doi: 10.1097/SLA.0b013e3182827a65.

PMID:
23470568
6.

Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors.

Yachida S, White CM, Naito Y, Zhong Y, Brosnan JA, Macgregor-Das AM, Morgan RA, Saunders T, Laheru DA, Herman JM, Hruban RH, Klein AP, Jones S, Velculescu V, Wolfgang CL, Iacobuzio-Donahue CA.

Clin Cancer Res. 2012 Nov 15;18(22):6339-47. doi: 10.1158/1078-0432.CCR-12-1215. Epub 2012 Sep 18.

7.

Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity.

Loukopoulos P, Kanetaka K, Takamura M, Shibata T, Sakamoto M, Hirohashi S.

Pancreas. 2004 Oct;29(3):193-203.

PMID:
15367885
8.

[Genetic aspects of pancreatic cancer].

Grigor'eva IN, Efimova OV, Suvorova TS, Tov NL.

Eksp Klin Gastroenterol. 2014;(10):70-6. Review. Russian.

PMID:
25911935
9.

Loss of DPC4 expression and its correlation with clinicopathological parameters in pancreatic carcinoma.

Hua Z, Zhang YC, Hu XM, Jia ZG.

World J Gastroenterol. 2003 Dec;9(12):2764-7.

10.

RUNX3 Controls a Metastatic Switch in Pancreatic Ductal Adenocarcinoma.

Whittle MC, Izeradjene K, Rani PG, Feng L, Carlson MA, DelGiorno KE, Wood LD, Goggins M, Hruban RH, Chang AE, Calses P, Thorsen SM, Hingorani SR.

Cell. 2015 Jun 4;161(6):1345-60. doi: 10.1016/j.cell.2015.04.048. Epub 2015 May 21.

11.

Loss of heterozygosity predicts poor survival after resection of pancreatic adenocarcinoma.

Franko J, Krasinskas AM, Nikiforova MN, Zarnescu NO, Lee KK, Hughes SJ, Bartlett DL, Zeh HJ 3rd, Moser AJ.

J Gastrointest Surg. 2008 Oct;12(10):1664-72; discussion 1672-3. doi: 10.1007/s11605-008-0577-9. Epub 2008 Aug 2.

PMID:
18677542
12.

Genetic and epigenetic alterations of familial pancreatic cancers.

Brune K, Hong SM, Li A, Yachida S, Abe T, Griffith M, Yang D, Omura N, Eshleman J, Canto M, Schulick R, Klein AP, Hruban RH, Iacobuzio-Donohue C, Goggins M.

Cancer Epidemiol Biomarkers Prev. 2008 Dec;17(12):3536-42. doi: 10.1158/1055-9965.EPI-08-0630.

13.

Alteration of somatostatin receptor subtype 2 gene expression in pancreatic tumor angiogenesis.

Qin RY, Fang RL, Gupta MK, Liu ZR, Wang DY, Chang Q, Chen YB.

World J Gastroenterol. 2004 Jan;10(1):132-5.

14.

Role of the DPC4 tumor suppressor gene in adenocarcinoma of the ampulla of Vater: analysis of 140 cases.

McCarthy DM, Hruban RH, Argani P, Howe JR, Conlon KC, Brennan MF, Zahurak M, Wilentz RE, Cameron JL, Yeo CJ, Kern SE, Klimstra DS.

Mod Pathol. 2003 Mar;16(3):272-8.

15.

Intraductal tubular carcinoma of the pancreas: case report with molecular analysis.

Furukawa T, Hatori T, Fukuda A, Fujita I, Yamamoto M.

Pancreas. 2009 Mar;38(2):235-7. doi: 10.1097/MPA.0b013e318175e3e0. No abstract available.

PMID:
19238030
16.

Evolution and dynamics of pancreatic cancer progression.

Yachida S, Iacobuzio-Donahue CA.

Oncogene. 2013 Nov 7;32(45):5253-60. doi: 10.1038/onc.2013.29. Epub 2013 Feb 18. Review.

17.

Low frequency of p53 and k-ras codon 12 mutations in non-small cell lung carcinoma (NSCLC) tumors and surgical margins.

Vatan O, Bilaloglu R, Tunca B, Cecener G, Gebitekin C, Egeli U, Yakut T, Urer N.

Tumori. 2007 Sep-Oct;93(5):473-7.

18.

Pancreatic acinar cell carcinomas with prominent ductal differentiation: Mixed acinar ductal carcinoma and mixed acinar endocrine ductal carcinoma.

Stelow EB, Shaco-Levy R, Bao F, Garcia J, Klimstra DS.

Am J Surg Pathol. 2010 Apr;34(4):510-8. doi: 10.1097/PAS.0b013e3181cfcac7.

PMID:
20182344
19.

Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas : a new marker of DPC4 inactivation.

Wilentz RE, Su GH, Dai JL, Sparks AB, Argani P, Sohn TA, Yeo CJ, Kern SE, Hruban RH.

Am J Pathol. 2000 Jan;156(1):37-43.

20.

Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).

Lim EH, Zhang SL, Li JL, Yap WS, Howe TC, Tan BP, Lee YS, Wong D, Khoo KL, Seto KY, Tan L, Agasthian T, Koong HN, Tam J, Tan C, Caleb M, Chang A, Ng A, Tan P.

J Thorac Oncol. 2009 Jan;4(1):12-21. doi: 10.1097/JTO.0b013e3181913e28.

Supplemental Content

Support Center